[Evaluation of the efficacy of silodosin 8 mg in comorbid patients with LUTS/BPH].

Autor:	Zimichev AA; Department of Urology of FGBOU VO Samara State Medical University, Samara, Russia.; Department of Surgical Diseases No. 2 of REAVIZ Medical University., Gusev DO; Department of Urology of FGBOU VO Samara State Medical University, Samara, Russia.; Department of Surgical Diseases No. 2 of REAVIZ Medical University., Lukyanova DY; Department of Urology of FGBOU VO Samara State Medical University, Samara, Russia.; Department of Surgical Diseases No. 2 of REAVIZ Medical University.
Jazyk:	ruština
Zdroj:	Urologiia (Moscow, Russia : 1999) [Urologiia] 2022 Dec (6), pp. 36-40.
Abstrakt:	Introduction: According to domestic and foreign publications, benign prostatic hyperplasia (BPH) is one of the most common urological diseases among older men, which prevalence reaches 50% by the age of 60. Aim: To analyze the efficiency of the use of the alpha1-blocker silodosin at a dose of 8 mg a day in comorbid patients with lower urinary tract symptoms (LUTS), associated with BPH. Materials and Methods: A total of 197 comorbid patients with LUTS/BPH were included in the study. All men underwent a standard examination. They were divided into 2 groups without differences in baseline parameters. In the main group (n=100) patients received silodosin at a dose of 8 mg, while in the control group 97 men did not receive any drug therapy for LUTS. Discussion: There were significant differences between groups in the total IPSS score, postvoid residual (ml), maximum urine flow rate (ml/s), patient satisfaction with treatment efficacy based on the TS-VAS visual analogue scale (total score). However, we didnt find significant differences in rate of cardiovascular side effects between the groups. Conclusions: Treatment of comorbid patients with LUTS/BPH with silodosin at a dose of 8 mg results in significant improvement and is not associated with cardiovascular adverse events.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu